Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Guardant Health","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Guardant Health and Blueprint Medicines Present Real-world Data Identifying EGFR C797x Mutation as Most Common Resistance Mechanism to Osimertinib Therapy at IASCLC 2022 World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Guardant Health","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360\u00ae CDx and Guardant360 TissueNext\u2122 as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Guardant Health

    Menu

    Guardant Health

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Guardant Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Adv...

              Details:

              Under the terms of the collaboration, Guardant Health and AnHeart Therapeutics will develop Guardant360® CDx and Guardant360 TissueNext™ assays as companion diagnostics for AB-106 (taletrectinib) in Advanced or Metastatic ROS1-Positive NSCLC.

              Lead Product(s): Taletrectinib

              Therapeutic Area: Oncology Product Name: AB-106

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: AnHeart Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Guardant Health

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Guardant Health and Blueprint Medicines Present Real-world Data Identifying EGFR C797x Mutation as Most Common Resistance Mechanism to Osimertinib Therapy at IASCLC 2022 Wo...

              Details:

              Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line Tagrisso (osimertinib) treatment.

              Lead Product(s): Osimertinib Mesylate

              Therapeutic Area: Oncology Product Name: Tagrisso

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Blueprint Medicines

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY